X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
antimyeloma activity (30) 30
humans (30) 30
index medicus (28) 28
multiple myeloma (24) 24
multiple myeloma - drug therapy (21) 21
oncology (21) 21
animals (16) 16
bortezomib (16) 16
hematology (16) 16
antineoplastic agents - pharmacology (13) 13
antineoplastic agents - therapeutic use (13) 13
multiple myeloma - pathology (12) 12
apoptosis (11) 11
multiple myeloma - metabolism (11) 11
cancer (10) 10
antitumor-activity (7) 7
cell line, tumor (7) 7
proteasome inhibitors (7) 7
signal transduction - drug effects (7) 7
apoptosis - drug effects (6) 6
bone-marrow (6) 6
boronic acids - pharmacology (6) 6
in-vitro (6) 6
in-vivo (6) 6
mice (6) 6
pyrazines - pharmacology (6) 6
activation (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
dexamethasone (5) 5
drug-resistance (5) 5
hematology, oncology and palliative medicine (5) 5
multiple myeloma - genetics (5) 5
multiple-myeloma (5) 5
proteasome endopeptidase complex - metabolism (5) 5
signal transduction (5) 5
thalidomide (5) 5
unfolded protein response (5) 5
article (4) 4
biochemistry & molecular biology (4) 4
boronic acids - therapeutic use (4) 4
cell biology (4) 4
drug resistance, neoplasm (4) 4
drug therapy (4) 4
female (4) 4
induced apoptosis (4) 4
inhibition (4) 4
lenalidomide (4) 4
lenalidomide plus dexamethasone (4) 4
leukemia (4) 4
nf-kappa-b (4) 4
pharmacology & pharmacy (4) 4
pomalidomide (4) 4
proteasome inhibitors - pharmacology (4) 4
proteasome inhibitors - therapeutic use (4) 4
proteins (4) 4
pyrazines - therapeutic use (4) 4
research (4) 4
survival (4) 4
xenograft model antitumor assays (4) 4
biology (3) 3
bone-marrow microenvironment (3) 3
bortezomib resistance (3) 3
chemistry, medicinal (3) 3
combination (3) 3
cytotoxicity (3) 3
diphosphonates - administration & dosage (3) 3
endoplasmic-reticulum stress (3) 3
er stress (3) 3
genetic aspects (3) 3
hematologic malignancies (3) 3
hsp90 heat-shock proteins - antagonists & inhibitors (3) 3
imidazoles - administration & dosage (3) 3
immunomodulation (3) 3
inhibitors (3) 3
male (3) 3
microenvironment (3) 3
molecular targeted therapy (3) 3
monoclonal-antibody (3) 3
multiple myeloma - mortality (3) 3
multiple myeloma - physiopathology (3) 3
multiple-myeloma cells (3) 3
overcomes drug-resistance (3) 3
phase-i (3) 3
plasma-cells (3) 3
proteasome (3) 3
proteasome inhibitor bortezomib (3) 3
stem-cell transplantation (3) 3
toxicity (3) 3
treatment outcome (3) 3
20s proteasome (2) 2
aged (2) 2
angiogenesis (2) 2
antimitotic agents (2) 2
antimyeloma (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
arsenic trioxide (2) 2
autophagy (2) 2
blotting, western (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia, ISSN 0887-6924, 08/2017, Volume 31, Issue 8, pp. 1760 - 1769
Journal Article
Leukemia, ISSN 0887-6924, 04/2010, Volume 24, Issue 4, pp. 843 - 850
Galectins constitute a family of lectins that specifically exhibit the affinity for beta-galactosides and modulate various biological events. Galectin-9 is a... 
H2AX | Galectin-9 | P38 | JNK | Multiple myeloma | multiple myeloma | ACTIVATION | ANTIMYELOMA ACTIVITY | MODIFIED VERSION | galectin-9 | DNA-DAMAGE | CELL APOPTOSIS | FAMILY | IN-VITRO | p38 | ONCOLOGY | ANIMAL LECTINS | SUPPRESSES | HEMATOLOGY | T-CELLS | Whole-Body Irradiation | Phosphorylation | Oligonucleotide Array Sequence Analysis | Apoptosis - drug effects | Humans | JNK Mitogen-Activated Protein Kinases - metabolism | Gene Expression Profiling | RNA, Messenger - metabolism | Multiple Myeloma - drug therapy | Biomarkers, Tumor - metabolism | Antineoplastic Agents - pharmacology | JNK Mitogen-Activated Protein Kinases - genetics | Proto-Oncogene Proteins - metabolism | Bortezomib | MAP Kinase Kinase Kinases - genetics | RNA, Messenger - genetics | Proto-Oncogene Proteins - genetics | MAP Kinase Kinase Kinases - metabolism | Recombinant Proteins - pharmacology | Multiple Myeloma - metabolism | Mutation - genetics | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Xenograft Model Antitumor Assays | Galectins - pharmacology | Multiple Myeloma - pathology | Animals | Signal Transduction - drug effects | Mice, Nude | Cell Line, Tumor | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Mice | Pyrazines - pharmacology | Boronic Acids - pharmacology | Lectins | Physiological aspects | Cellular signal transduction | Genetic aspects | Research | Drug therapy | Health aspects | Mitogen-activated protein kinases
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 04/2013, Volume 161, Issue 1, pp. 104 - 116
Summary Despite considerable advances, multiple myeloma (MM) remains incurable and the development of novel therapies targeting the interplay between plasma... 
microenvironment | multiple myeloma | NSG | antimyeloma agents | chemotaxis | Antimyeloma agents | Microenvironment | Chemotaxis | Multiple myeloma | APOPTOSIS | ACTIVATION | BORTEZOMIB | RELEASE | THALIDOMIDE | COMBINATION | MULTIKINASE INHIBITOR | CYTOCHROME-C | GROWTH | HEMATOLOGY | PHASE-I | Niacinamide - analogs & derivatives | Apoptosis - drug effects | Humans | Middle Aged | Actins - metabolism | Male | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Chemokine CXCL12 - antagonists & inhibitors | Dose-Response Relationship, Drug | Polymerization - drug effects | Multiple Myeloma - drug therapy | Female | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Tumor Cells, Cultured | Tumor Microenvironment - drug effects | Bortezomib | Neoplasm Proteins - biosynthesis | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Chemotaxis - drug effects | Down-Regulation - drug effects | Mice, SCID | Multiple Myeloma - metabolism | Niacinamide - administration & dosage | Xenograft Model Antitumor Assays | Multiple Myeloma - pathology | Animals | Mitogen-Activated Protein Kinase 3 - metabolism | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemokine CXCL12 - pharmacology | Syndecan-1 - biosynthesis | Mice, Inbred NOD | Aged | Mice | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Mitogen-Activated Protein Kinase 1 - metabolism | Antimitotic agents | Cell death | Actin | Polymerization | Amyloidosis | Biochemistry | Antineoplastic agents | Muscle proteins
Journal Article
Leukemia, ISSN 0887-6924, 2014, Volume 28, Issue 3, pp. 525 - 542
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 04/2011, Volume 8, Issue 4, pp. 200 - 209
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 21, pp. 5228 - 5236
Nuclear factor-kappa B (NF-kappa B) has an important role in multiple myeloma (MM) cell pathogenesis in the context of the bone marrow (BM) microenvironment.... 
ADHESION | ACTIVATION | RESISTANCE CAM-DR | BONE-MARROW MICROENVIRONMENT | BETA INHIBITOR | ANTIMYELOMA ACTIVITY | ALPHA | MECHANISMS | CELL-GROWTH | HEMATOLOGY | CANCER | Lymphoid Neoplasia
Journal Article